Annabelle Stoclin

Annabelle Stoclin

Auto-generated profile, based on publicly available information

Annabelle Stoclin

Gustave Roussy, Service de réanimation et de soins intensifs, 94805 Villejuif, France; Gustave Roussy, Department d'Hématologie Clinique, 94805 Villejuif, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
AGArthur GERAUD
Arthur GERAUD
THThomas Hueso
Thomas Hueso
ALAriane Laparra
Ariane Laparra
NBNaike Bige
Naike Bige
KOKaissa Ouali
Kaissa Ouali
Jean Marie MichotJean Marie Michot
Jean Marie Michot

30 July 2020 in Critical Care Medicine
Verified
Journal Article
Closed access
AMAurélien Mazeraud
Aurélien Mazeraud
APAndrea Polito
Andrea Polito
SSSivanthiny Sivanandamoorthy
Sivanthiny Sivanandamoorthy
RPRaphaël Porcher
Raphaël Porcher
NHNicholas Heming
Nicholas Heming
T(The Groupe D’eXplorations Neurologiques En Réanimation (Gener)
The Groupe D’eXplorations Neurologiques En Réanimation (Gener)
Objectives: Anxiety results from the anticipation of a threat and might be associated with poor outcome in the critically ill. This study aims at showing that anxiety at admission in critically ill patients is associated with new organ failure over the first 7 days of ICU hospitalization independently of baseline organ failure at admission. Design: Prospective multicenter cohort study. Setting: Three mixed ICU from April 2014 to December 2017. Patients: Coma-, delirium-, and invasive mechanical ventilation-free patients admitted to the ICU were included. Interventions: None. Measurements and Main Results: “State anxiety” was assessed using the state component of the State-Trait Anxiety Inventory State. Severity of illness was measured using Simplified Acute Physiology Score II and Sequential Organ Failure Assessment scores. Primary endpoint was a composite of occurrence of death or new organ failure in the first 7 days after admission. Three hundred ninety-one patients were included; 159 of 391 women (40.7%); median age 63 years (49–74 yr); median Simplified Acute Physiology Score II 28 (19–37). Two hundred three out of 391 patients (51.9%) reported moderate to severe anxiety (State-Trait Anxiety Inventory State ≥ 40). One hundred two out of 391 patients (26.1%) developed a new organ failure. After adjustment to Simplified Acute Physiology Score II and Sequential Organ Failure Assessment, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with the primary endpoint (odds ratio, 1.94; 95% CI, 1.18–3.18; p = 0.009) and respiratory failure. In post hoc analysis, State-Trait Anxiety Inventory State greater than or equal to 40 was associated with new organ failure independently and notably of respiratory status at admission (dyspnea-Visual Analogic Scale and Paco 2 ≥ 45 mm Hg). Conclusions: Moderate to severe anxiety at ICU admission is associated with early occurrence of new organ failure in critically ill patients, independently of respiratory status and severity of critical illness. The causality link could be addressed in an interventional trial.

30 May 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
SLStephane Legriel
Stephane Legriel
Rafael BadenesRafael Badenes
Rafael Badenes
NENicolas Engrand
Nicolas Engrand
RMRocio Mendoza-Trujillo
Rocio Mendoza-Trujillo
PSPauline Soulier
Pauline Soulier
NMNicolas Mongardon
Nicolas Mongardon
Objective: To report the prevalence of acute encephalopathy and outcomes in patients with severe COVID-19, and to identify determinants of 90-day outcomes. Methods: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated in six countries (France, USA, Colombia, Spain, Mexico, Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium, or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale−Extended score (GOS-E) of 1−4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Results: Of 4060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or prior to the ICU admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age >70 years (odds ratio [OR] 4.01, 95% confidence interval [CI], 2.25−7.15), presumed fatal comorbidity (3.98, 1.68−9.44), Glasgow Coma Scale score <9 before/at ICU admission ICU admission (2.20, 1.22−3.98), vasopressor/inotrope support during ICU stay (3.91, 1.97−7.76), renal replacement therapy during ICU stay (2.31, 1.21−4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (3.22, 1.41−7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03−0.83). Conclusions and Relevance: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in COVID-19 patients. Over a half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. Trial Registration: The study is registered with ClinicalTrials.gov, number NCT04320472

27 November 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AMAnahita Mostaghim
Anahita Mostaghim
SMSamuel Minkove
Samuel Minkove
JAJuan Aguilar-Company
Juan Aguilar-Company
IRIsabel Ruiz-Camps
Isabel Ruiz-Camps
SESimeon Eremiev-Eremiev
Simeon Eremiev-Eremiev
ACAlessio Cortellini
Alessio Cortellini
To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19. The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs. Of 3523 patients screened, 137 ICI-only and 1378 non-ICI met inclusion criteria. Before matching, ICI patients were older, male, enrolled at centers in Italy, and had histories of smoking, thoracic cancers, advanced cancer stages, and active malignancies (P ≤0.02). After matching, there were 120 ICI and 322 non-ICI patients. ICI patients had no differences (odds ratio: 95% CI) in presenting COVID-19 symptoms (0.69: 0.37-1.28), receipt of COVID-specific therapy (0.88: 0.54-1.41), 14-day (0.95: 0.56-1.61), or 28-day (0.79: 0.48-1.29) mortalities. However, ICI patients required less COVID-19-related hospitalization (0.37: 0.21-0.67) and oxygen therapy (0.51: 0.31-0.83) and developed fewer complications (0.57: 0.36-0.92). In this propensity-score matched analysis, previous ICI therapy did not worsen and potentially improved COVID-19 outcomes in patients with cancer.

5 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AGAnne-Gaëlle Goubet
Anne-Gaëlle Goubet
ADAgathe Dubuisson
Agathe Dubuisson
AGArthur GERAUD
Arthur GERAUD
FDFrançois-Xavier Danlos
François-Xavier Danlos
STSafae Terrisse
Safae Terrisse
LDLisa Derosa
Lisa Derosa
Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19 + ), we found that malignant disease favors the magnitude and duration of viral RNA shedding concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, activated follicular T helper cells, and non-naive Granzyme B + FasL + , Eome high TCF-1 high , PD-1 + CD8 + Tc1 cells. Virus-induced lymphopenia worsened cancer-associated lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA shedding, COVID-19 severity and a higher risk of cancer-related death in the first and second surge of the pandemic. Lymphocyte loss correlated with significant changes in metabolites from the polyamine and biliary salt pathways as well as increased blood DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term viral carriers. We surmise that cancer therapies may exacerbate the paradoxical association between lymphopenia and COVID-19-related immunopathology, and that the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated death.

1 January 2007 in Revue des Maladies Respiratoires
Verified
Journal Article
Closed access
CAC. Andréjak
C. Andréjak
BBB. Bazelly
B. Bazelly
HPH. Prigent
H. Prigent
APA. Parrot
A. Parrot
ASA. Stoclin
A. Stoclin
MFM. Fartoukh
M. Fartoukh